Valvuloplasty catheter

ABSTRACT

The present invention provides an aortic valvuloplasty catheter which, in one preferred embodiment, has a tapered distal balloon segment that anchors within the left ventricle outflow track of the patient&#39;s heart and a rounded proximal segment which conforms to the aortic sinuses forcing the valve leaflets open. In addition, this embodiment of the valvuloplasty catheter includes a fiber-based balloon membrane, a distal pigtail end hole catheter tip, and a catheter sheath.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional application60/488,635, entitled Enhanced Dilatation Catheter For Treatment OfAortic Stenosis, filed Jul. 18, 2003 and U.S. Provisional application60/547,896 entitled Catheter For Treatment of Aortic Valves, filed Feb.25, 2004, the entire contents of each being hereby incorporated byreference.

FIELD OF INVENTION

This invention relates to balloon catheters and other related mechanicaldevices for medical use. More particularly, this invention relates toballoon catheters with advanced anchoring and valvuloplastycapabilities. The invention also relates to controlling the expansionand force properties of a balloon in a balloon catheter through variousmeans, including the reinforcement of the balloon through fibers locatedon the balloon.

BACKGROUND OF THE INVENTION

Calcific aortic stenosis is a common cause of acquired valvular heartdisease with substantial morbidity and mortality. Its incidenceincreases exponentially in older patient populations. Fibrosis,degeneration and subsequent calcification are no longer believed to bepassive or purely degenerative in nature, but in fact are predominantlyactive processes mediated by underlying cellular mechanisms. Over time,as fibrosis and calcification worsens, valve leaflets becomeincreasingly rigid, restricting their ability to open. This in turn,then impedes the antegrade flow of blood through the heart resulting inseveral clinical syndromes including most significantly progressiveheart failure. Other causes of deformed and stenotic aortic valvularlesions include rheumatic heart disease, as well as nonacquired (i.e.congenital) heart disease. Initial stages of stenotic valvular heartconditions are well tolerated by the patient, but when leafletrestriction becomes severe, drastic measures such as aortic valvereplacement have commonly been required.

With the advent of catheter-based cardiovascular procedures, minimallyinvasive valvuloplasty techniques were developed to dilate stenosedvalves, most commonly calcific aortic stenosis but also rheumatic andcongenitally stenosed leaflets using catheter balloons. During thisprocedure, a catheter having a deflated balloon is percutaneouslyinserted into a vein or artery and advanced until the balloon ispositioned within the heart valve needing treatment. The balloon is theninflated to dilate the diseased valve opening, disrupting the rigidsheets of calcium permitting enhanced leaflet mobility. Balloondilation, depending on the disease process, may result not only in thedevelopment of numerous flexible hinge points within fibrosed andcalcified leaflets but, in addition, separation of fused commissures cantake place. After the leaflets have been dilated, the balloon isdeflated and removed from the patient's cardiovascular system.

In many current instances, valvuloplasty is performed with polyethyleneballoon catheters which can achieve relatively high pressures at a fixeddiameter. Balloons made of non-distensible plastic materials areexpanded using fluid pressure up to a certain diameter after which,increases in fluid pressure within the balloon produce very littlechange in balloon diameter. These balloons can achieve high pressuresfor an effective therapy, but inherent to this plastic material areseveral limitations. The profile of these balloons can be somewhatreduced by prefolding during the manufacturing process. However, onceinflated, the folded balloon segments are expanded within the vascularsystem and when deflated for removal, do not return to their compact,prefolded state but to a flattened state with a much larger profile.Withdrawal of these balloons therefore requires larger vascularintroductory sheaths and thereby increases the risk of trauma to thevessels, resulting in compromised blood flow to an extremity or postoperative bleeding. Additionally, non-distensible balloons also havethick cones—transitions from the cylindrical diameter to the cathetershaft diameter. These regions of the balloon make the catheter stiffincreasing the risk of vascular trauma and making it difficult toadvance through tortuous peripheral arterial anatomy.

Since the radial dimensions of the catheter balloon must greatlyincrease when inflated to achieve aortic valve dilation, a highlyelastic material such as latex can be used, but with significantlimitations. Distensible balloons use these elastic materials andgenerally have excellent initial profiles and improved flexibility forintroduction and travel through the vascular system. In addition, theypossess good deflated profiles for removal from the vascular system.However, elastic materials such as this continue to expand in diameteras pressure increases and therefore have no inherent limit on maximaldiameter as with non-distensible balloons. Thus, distensible balloonscan be unsafe for such a purpose as valvuloplasty, as the elastic limitcan easily be exceeded when the balloon is fully inflated, potentiallycausing the balloon to rupture within the patient. Additionally, theballoon diameters can become too large for the valve being dilatedcausing rupture and tearing of both the valve and its adjacentstructures.

In addition, prior art catheter balloons have been associated withmechanical injury to the cardiac chambers, especially near theventricular apex, due to the forceful longitudinal movement of theinflated balloon across the valve and within the cardiac chamber as theheart beats. Blood, and the vascular wall surface, are inherentlyslippery against common catheter balloons further increasing the risk ofsignificant balloon migration. As inflation fluid (contrast media) isintroduced, the catheter balloon enlarges and eventually assumes acylindrical or ovoid shape. This creates a tendency for the balloon tosuddenly and uncontrollably pop in and out of the valve site and migratedeep into the left ventricle. In some situations, this sudden balloonmovement following inflation has not only made it difficult to positionaccurately within the valve leaflets but again has led to damage andeven catastrophic puncturing of the left ventricle.

Further, typical catheter balloon shapes tend to completely obstruct theflow of blood through the heart while inflated. Without perfusionthrough or around the catheter, the catheter balloon inflation time islimited to a few seconds before risking complications due to profoundhypotension.

A further disadvantage of prior art valvuloplasty balloons is theirfrequent failure to restore adequate flexibility to the aortic valveleaflets. That is, mere dilation with these previous balloon designs maynot be enough to adequately open the severely fibrosed and calcifiedleaflets. The prior art balloon catheters are cylindrical in shape whenfully inflated and thus have their maximal inflated diameter limited bythe narrower sinotubular ridge and valve annulus at the proximal anddistal margins of the aortic root sinuses. Efforts to expand beyondthese limits for enhanced valve opening can result in tearing of theaortic valve annulus, catastrophic aortic insufficiency or rupture ofthe aortic root. In addition, traditional balloon catheter methodsgenerally result in eventual restenosis of the aortic valve leaflets,negating some or all of the regained flexibility.

Examples of some of these prior art catheter designs, as well as otherrelated catheter designs are discussed and disclosed in the followingU.S. patent documents: U.S. Pat. Nos. 4,327,736; 4,777,951; 4,787,388;4,878,495; 4,819,751; 4,909,252; 4,986,830; 5,352,199; and 5,947,924.

What is needed is a balloon valvuloplasty catheter that overcomes all ofthe these disadvantages of the prior art. Indeed, what is needed is aninvention that not only overcomes the disadvantages of the prior art intreating calcific aortic stenosis but also aortic stenosis resultingfrom congenitally abnormal valves and/or rheumatically injured valves.

Of particular need is a balloon configuration that has expansioncharacteristics that not only stabilize the valvuloplasty catheter at adesired location but that also provides the necessary a-traumaticexpansion force to successfully perform the valvuloplasty. Moreover, itis desired to meet this need either with a single reinforced balloonconfiguration or a dual balloon configuration.

OBJECTS AND SUMMARY OF THE INVENTION

It is an object of the present invention to provide a balloon catheterthat overcomes the shortcomings of the prior art.

It is a further object of the present invention to provide a catheterthat can anchor itself so as to create a stable catheter position duringvalvuloplasty.

It is an object of the present invention to provide a tapered distalballoon catheter segment which is better able to anchor itself withinthe left ventricular outflow tract. Anchoring to create stable catheterpositions for valvuloplasty can also be accomplished by other novelembodiments introduced in this patent application.

It is a further object of the present invention to provide a ballooncatheter segment that conforms more accurately to the valve annular ringto prevent over stretching, mechanical trauma, or even tearing of thissupporting structure.

It is yet a further object of the present invention to provide a roundedproximal balloon catheter segment that conforms to the shape of theaortic root to improve leaflet opening by creating broader and moreeffective hinge points on the aortic valve leaflets.

It is yet a further object of the present invention to provide a ballooncatheter which allows antegrade (forward) perfusion of blood.

It is a further object of the present invention to overcome thedisadvantages of the prior art.

It is a further object of the present invention to provide a drugdelivery device for providing local anti-restenotic therapies andtherapies to result in stenosis regression.

The present invention achieves these objects by providing an aorticvalvuloplasty catheter which, in one preferred embodiment, has a tapereddistal balloon segment that anchors within the left ventricle outflowtrack of the a patient's heart and a more proximal rounded segment tobroadly dilate the aortic valve leaflets into the aortic root sinuses.In addition, this embodiment of the valvuloplasty catheter may include afiber-based balloon membrane to aid in achieving a lower profile, higherpressure balloon with a specific geometric shape. In addition, thisembodiment may be configured to permit distal perfusion while theballoon is inflated. It may have a pigtail distal tip to minimize anylikelihood of intracardiac trauma. The entire catheter may be advancedthrough an elongated sheath to assure greater stability and permitmeasurement of central aortic pressures.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates a side view of an valvuloplasty catheter according tothe present invention;

FIGS. 2A-2B illustrate a side view of the valvuloplasty catheter of FIG.1;

FIG. 3 illustrates a side view of a catheter sheath according to thepresent invention;

FIG. 4 illustrates a side view of a valvuloplasty catheter with a debrisbasket according to the present invention;

FIGS. 5A-5C illustrate side views of a single balloon valvuloplastycatheter according to the present invention;

FIGS. 5D-5L illustrate side view of a single balloon valvuloplastycatheter using various fiber reinforced balloon characteristics inaccordance with the present invention;

FIGS. 6A-6C illustrate side views of a ring and balloon catheteraccording to the present invention;

FIG. 7A illustrates a side view of a longitudinal wire catheteraccording to the present invention;

FIG. 7B illustrates a top view of a wire mounting ring of thelongitudinal wire catheter of FIG. 7A;

FIG. 8 illustrates a side view of a center channel catheter according tothe present invention;

FIG. 9 illustrates a side view of a center channel catheter according tothe present invention;

FIGS. 9A-9B illustrates a side view and a top view of a center channelcatheter according to the present invention;

FIG. 10A illustrates a side view of a valvuloplasty perfusion catheteraccording to the present invention;

FIG. 10B illustrates a bottom view of the valvuloplasty perfusioncatheter of FIG. 10A;

FIG. 11A illustrates a side view of a dual balloon valvuloplastycatheter according to the present invention;

FIG. 11B illustrates a top view of the dual balloon valvuloplastycatheter of FIG. 11A;

FIGS. 12A-12C illustrate side views of an valvuloplasty catheteraccording to the present invention;

FIGS. 13A-13B illustrate side views of an valvuloplasty catheteraccording to the present invention;

FIG. 14A illustrates a side view of a petal anchoring catheter accordingto the present invention;

FIG. 14B illustrates a top view of petals of the petal anchoringcatheter of FIG. 14A;

FIGS. 15A-15B illustrate a petal anchoring catheter according to thepresent invention;

FIG. 15C illustrates a top view of petals of the petal anchoringcatheter of FIG. 15A;

FIG. 16 illustrates a side view of a drug eluting device according tothe present invention;

FIG. 17A illustrates a side view of a drug eluting device according tothe present invention;

FIG. 17B illustrates a top view of the drug eluting device according inFIG. 17A;

FIG. 18 illustrates a top view of a drug eluting device according to thepresent invention;

FIG. 19 illustrates a side view of a drug eluting device according tothe present invention;

FIG. 20A illustrates a side view of a drug eluting device according tothe present invention;

FIG. 20B illustrates a side view of the membrane of the drug elutingdevice of FIG. 20A;

FIG. 20C illustrates a side view of a locking post of the drug elutingdevice of FIG. 20A;

FIG. 21A illustrates a side view of an valvuloplasty catheter accordingto the present invention;

FIG. 21B illustrates a bottom view of the valvuloplasty catheter of FIG.21A;

FIG. 21C illustrates a side view of the valvuloplasty catheter of FIG.21A;

FIG. 21D illustrates a side view of the valvuloplasty catheter of FIG.21A;

FIGS. 21E-21K illustrate various top and side views of a valvuloplastycatheter that has perfusion channels which are formed by fiberreinforced structures in accordance with the present invention;

FIG. 22 illustrates a side view of an off center valvuloplasty catheteraccording to the present invention; and

FIGS. 23A-23C illustrate a side view of a mesh anchoring valvuloplastycatheter according to the present invention.

DETAILED DESCRIPTION OF THE INVENTION

During a typical valvuloplasty procedure, a balloon catheter is insertedpercutaneously within a patient's vessel and advanced to a stenoticvalve, for example, the aortic valve which is contiguous with the leftventricle of the heart. Once in a desired position within a valve, thecatheter balloon is inflated with liquid contrast media, expanding thediameter of the balloon and forcing the valve leaflets open. By forcingthe valve open for a brief time, the leaflets are able to regain atleast a portion of their original flexibility, allowing for more normalcardiovascular function.

Aortic Valvuloplasty Catheter

Turning to FIGS. 1, 2A, and 2B, a preferred embodiment of an aorticvalvuloplasty catheter 100 is illustrated in accordance with the presentinvention, having an elongated catheter shaft 106 with a proximal,aortic sinus dilatation balloon 102 and a distal LVOT anchoring balloon104 at the distal end of the catheter shaft 106. The distal anchoringballoon 104 provides anchoring support to the valvuloplasty catheter 100by expanding within the left ventricular outflow tract 130 (LVOT), thusallowing the aortic sinus balloon 102 to maintain a desired position toexpand against the aortic valve leaflets 126.

The catheter shaft 106 has multiple lumens (not shown) positionedaxially within the catheter shaft 106 body, similar to those used forballoon angioplasty catheters. Each of the lumens opens at a proximalend of the catheter shaft 106, within the control hub 116, andterminates at varying points near the distal end of the catheter shaft106, such as at a proximal aortic sinus balloon port 110 or a distalanchoring balloon port 112. Typically, the catheter shaft 106 has atleast 3 lumens: a lumen for a guide wire 118, a lumen to communicate aninflation media to the aortic sinus balloon port 110, and a lumen tocommunicate an inflation media to the anchoring balloon port 112. Notethat connecting fittings 120 and 122 can be seen in FIG. 1, whichconnect the two inflation lumens to external media supplies (not shown).Additional lumens for pressure measurement could be added to thiscatheter for simultaneous aortic and left ventricular pressures toderive aortic valve gradients pre and post valvuloplasty.

Additionally, radiopaque markers 114 are positioned at various locationson the catheter shaft 106, to mark, for example, the proximal and distalboundaries of the aortic sinus balloon 102 and the distal anchoringballoon 104. As such, the radiopaque markers 114 serve as visual guidesduring a valvuloplasty procedure to further assist positioning theenhanced aortic valvuloplasty catheter 100 of the present invention in adesired position within a patient's vascular system.

An angulated pigtail 108 is located at the distal end of catheter shaft106 to prevent mechanical damage to the patient while the enhancedvalvuloplasty catheter 100 is operated. The angulated pigtail 108 has asingle hole (not shown) at its immediate distal end for passage of aguide wire and pressure measurement after the guide wire is removed. Thesingle end hole design provides a more accurate pressure measurementwhen the balloon segments are retracted proximal to the aortic valve,leaving just the pigtail within the left ventricle. In comparison, apigtail 108 with multiple side holes disposed along the length of thepigtail section can leave some of the holes proximal as well as distalto the valve, leading to inaccurate valve gradient measurements. Itshould be noted, however, that multiple side holes can be included inthe angulated pigtail 108 for additional uses, such as radiopaque dyeinjections, or other purposes.

The distal anchoring balloon 104 is located at the distal end ofcatheter shaft 106, near angulated pigtail 108. The distal anchoringballoon 104 inflates with media communicated by anchoring balloon port112, so as to press against the structure of the LVOT, fixing thelongitudinal position of the aortic valvuloplasty catheter 100.Preferably, the cross sectional surface contour of the distal anchoringballoon 104 does not engage the LVOT throughout its entirecircumference. This will permit perfusion around the distal anchoringballoon 104. For example, the distal anchoring balloon 104 may have across sectional shape of a star, spiral, or donut, of which additionaldetails and examples are discussed in greater detail below. However, adistal anchoring balloon 104 that engages the entire circumference ofthe LVOT may be used so long as it is operated by quick inflationfollowed by quick deflation.

Prior art catheter balloons have been associated with mechanical injuryto the heart, especially near the ventricular apex, due to the strongtendency for the inflated balloon to abruptly migrate back and forthacross the aortic valve, darting in and out of the left ventricle due tophasic blood flow. Accordingly, the distal anchoring balloon 104 of thecatheter 100 of the present invention preferably has a reverse taperdistally where it would be larger in diameter. In this manner, thedistal anchoring balloon 104 more closely conforms to the anatomicalstructure of the LVOT, preventing abrupt back and forth movement. Itshould be noted that the distal LVOT anchoring balloon 104 can be shapedto many different forms, who's purpose it is again to more tightlyengage the LVOT for longitudinal fixation. An example includes an hourglass configuration to accommodate the hypertrophic, i.e. proximal, leftventricle septal bulge seen in many patients. A more adhesive balloonsurface can be created by an external balloon fiber or other implants toprevent balloon slippage.

Preferably, the distal anchoring balloon 104 functions under lowinflation pressure, for example less than about 3 atm. The distalanchoring balloon 104 is sized to engage the LVOT of a patient, havingthe preferable exemplary dimensions of about 15-20 mm in length, 24-28mm in diameter for the distal end and 20-24 mm in diameter for theproximal end. However, since the size and shape of a LVOT may vary frompatient to patient, the final distal anchoring balloon 104 size andshape may be selected to more closely conform to each LVOT.

The aortic sinus balloon 102 is located proximal to the distal anchoringballoon, having a sinus balloon port 110 to communicate media forinflating the aortic sinus balloon 102 against the valve leaflets 126.When inflated, the aortic sinus balloon 102 preferably conforms to therounded shape of the aortic sinuses (as best seen in FIG. 2B), enablingthe leaflets 126 to be opened as broadly as possible. This roundedproximal segment 192 would in fact permit hyperextension of the valveleaflets 126 into the aortic sinuses 123, yielding greater valve leafletopening and consequently greater reduction in aortic valve gradient. Itpreferably is distensible through a wide range of predetermineddiameters to take advantage of the range of diameters seen for theaortic sinuses in various patients. For example, the inflated aorticsinus balloon 102 may preferably be capable of achieving a balloondiameter of about 24 mm at about 4 ATMs of pressure and about 28 mm at 6ATMs of pressure. Alternately, the aortic sinus balloon 102 can beprimarily volume driven so that the balloon will achieve a range ofdiameters determined by the volume of media instilled. Preferably, theaortic sinus balloon 102 is about 18 mm in length, with a maximaldiameter of about 24-30 mm.

Both the aortic sinus balloon 102 and the distal anchoring balloon 104may be composed of a semi-elastic plastic. However, as higher pressuresare utilized, especially for the aortic sinus balloon 102, the balloonmembrane typically must substantially increase in thickness to guardagainst rupture of the balloon 102. Furthermore, the resultant need fora larger vascular entry sheath results in the inherent risk forpercutaneous vascular injury. In this regard, fiber-based membranes arepreferably used for both balloons 102 and 104 to increase the balloonmembrane strength without the need to substantially increase thickness.The fabric reinforced balloon is also capable of allowing the formationof a specified geometric shape to the expanded balloon. Examples of suchfiber based balloon membranes can be seen in the currently pending andcommonly owned U.S. patent application Ser. No. 09/974,220, entitledMaterial Useable For Medical Balloons And Catheters, filed Oct. 9, 2001,the contents of which are herein incorporated by reference.

As seen in FIGS. 2A-3, an elongated sheath 124 may be used to introducethe valvuloplasty catheter 100 and assist in stabilizing it across theaortic valve during inflation, by preventing back and forth motion.Additionally, the sheath 124 can be used to measure the central aorticpressure which is useful for perioperatively monitoring and indetermining the aortic valve pressure gradient following valve dilation.The sheath 124 may be used with the present preferred embodiment or anyother of the subsequent embodiments described within this application.

In operation, the aortic valvuloplasty catheter 100 of the presentinvention is introduced through the femoral or brachial artery using aSeldinger technique to place a vascular sheath introducer in theperipheral vessel. After placement of a guidewire (not shown) across theaortic valve, the aortic valvuloplasty catheter 100 of the presentinvention is advanced retrograde over the guidewire such that thepigtail 108 is positioned in the left ventricle. Next, the distalanchoring balloon 104 is positioned using fluoroscopy within the LVOT130, just underneath the valve annulus 125. The distal anchoring balloon104 is inflated with fluid, e.g., contrast media, which is communicatedthrough anchoring balloon inflation port 112, best seen in FIG. 2A. Thedistal anchoring balloon 104 expands in diameter as contrast media isadded, allowing the distal anchoring balloon 104 to engage and pressagainst the walls of the LVOT 130, thus longitudinally securing theposition of the enhanced aortic valvuloplasty catheter 100. Once thedistal anchoring balloon 104 is anchored securely within the LVOT 130,the aortic sinus balloon 102 is inflated, as seen in FIG. 2B,hyper-extending the valve leaflets 126 into the rounded aortic sinuses123. In this regard, it may be necessary to inflate the aortic sinusballoon 102 at several different diameters to achieve the desired valveleaflet 126 flexibility and therefore the desired pressure gradientreduction. To ensure these goals have been achieved, the pressuregradient is measured using the distal guidewire lumen after the balloons102, and 104 are withdrawn proximal to the aortic valve, leaving thepigtail 108 within the LVOT distal to the valve leaflets 126. A lumenwithin the sheath 124 may then be connected to a pressure transducer(not shown) at the proximal end of the sheath 124. Simultaneous centralaortic and left ventricle pressure can then be measured to derive thevalve gradient.

Microporous Filter Basket

FIG. 4 illustrates another preferred embodiment of the presentinvention, in which an aortic valvuloplasty catheter 100 in accordancewith the present invention includes a microporous filter basket 143. Theaortic valvuloplasty catheter 100 is configured and operated in analmost identical manner as described previously. However, a microporousfilter basket 143 is included proximal to the aortic sinus balloon 102to catch any debris resulting from the valvuloplasty procedure andthereby prevent embolic complications in the patient. For example,aortic root or valve leaflet debris or thrombus may dislodge with theinflation of aortic sinus balloon 102. If these deposits or thrombus arenot captured, e.g. by the microporous filter basket 143, such particlescan travel to the brain, as well as other organs systems, causing strokeor other ischemic injury.

The microporous filter basket 143 is made up of multiple basket arms 142which are pre-set in an expanded, open position. The proximal ends ofthe basket arms 142 are fixed to an anchor point on the enhanced aorticvalvuloplasty catheter 100, while the distal ends of the basket arms 142are self deployed against the ascending aorta 128. A microporous filter141 is secured to the basket arms 142, creating an enclosed basketshape.

In operation, the microporous filter basket 143 remains packed withinthe sheath 124 while in a pre-deployed state. During this time, thebasket arms 142 are pressed against the catheter body 106, while themicroporous filter 141 is packed between the catheter body 106 and thesheath 124. When a user has positioned the aortic valvuloplasty catheter100 at a desired location and wishes to deploy the microporous filterbasket 143, the sheath 124 is retracted in a proximal direction,exposing the microporous filter basket 143 and allowing the pre-setbasket arms 142 to expand and engage the aortic wall 128. Thus, ifdebris breaks loose during the valvuloplasty procedure, the filterbasket 143 prevents this debris from traveling downstream into thevascular system. When the user removes the aortic valvuloplasty catheter100, the sheath 124 is moved in a distal direction toward the filterbasket 143 or the catheter 100 is retracted into the sheath 124, causingthe filter basket 143 to compress in diameter and slide within thesheath 124.

The material constituting the filter basket may be comprised of thenanoskin material as disclosed in co-pending application Ser. No.10/314,086, filed Dec. 6, 2002, entitled Covering And Method UsingElectrospinning Of Very Small Fibers, the contents of which areincorporated by reference.

Single Balloon Valvuloplasty Catheter

Referring now to FIGS. 5A-5B, a single balloon valvuloplasty catheter200 is illustrated, having a single catheter balloon 202 instead of twodistinct balloons as in previously described embodiments.

Generally speaking, the single balloon valvuloplasty catheter 200 isconfigured with a similar structure to previously described embodiments.The single balloon valvuloplasty catheter 200 has a multi-lumen catheterbody 204 with radiopaque markers 203 located at reference points on thedistal portion of catheter body 204. A guidewire is positioned through alumen within the catheter body 204 and extends out the distal end of thecatheter body 204, which terminates in a pigtail shape 206. The catheterbody 204 has a media port 201, positioned in the mid section of thecatheter balloon 202, so as to allow communication with the media lumenin the catheter body 204.

The catheter balloon 202 preferably allows for progressive inflation, sothat the distal anchoring section 202 b of the catheter balloon 202inflates before the proximal aortic portion 202 a. This progressiveinflation may be accomplished with catheter balloon sections havingdiffering compliancy. For example, the distal anchoring portion 202 bmay have a relatively high compliance (e.g. about 24 ATM), while theproximal aortic portion 202 a may have a relatively low compliance (e.g.about 4-8 ATM). Thus, as inflation media enters the catheter balloon202, the more compliant section (i.e. the distal anchoring portion 202b) expands first. When the more compliant section fully expands, thepressure within the catheter balloon begins to increase further,allowing the less compliant section to begin expanding (i.e. theproximal aortic portion 202 a). The balloon diameter of the proximalportion of the LVOT segment 202 b, adjacent to the valve annulus 125, isrestricted from growing substantially beyond the diameter of the annulus125 by strategically positioning circumferential fiber reinforcement. Inthis manner, a user can precisely control the expansion sequence andmaximal achieved diameter for each of the catheter balloon sections 202a, 202 b.

When expanded, the proximal catheter balloon section 202 a substantiallyconforms to the rounded contour of the aortic sinus root 123. Byconforming closely to the aortic sinus root 123, the proximal catheterballoon section 202 a may open the leaflets 126 by hyperextending themopen as broadly as possible, reducing the possibility of tearing thevalve annulus 125.

The compliance of each of the catheter balloon sections 202 a, 202 b canbe obtained by utilizing fabric reinforcements at areas requiringadditional strength. Preferably, fiber based membranes, as previouslydescribed in this application and in pending application Ser. No.09/974,220 entitled Material Usable for Medical Balloons and Catheters(incorporated by reference), can be used to control the varyingcompliancy of the catheter balloon 202.

For example, referring to FIGS. 5D-5F, the balloon 202 in one embodimentmay be designed such that the LVOT segment 202 b of the balloon 202 isnot fiber-reinforced and thus displays compliant characteristics aspressure is introduced into the balloon 202 while the proximal aorticportion 202 a is fiber-reinforced (e.g., with yarns) and thus displaysnon-compliant characteristics. More specifically, in this oneembodiment, the LVOT segment 202 b is unreinforced and expandscompliantly during an introduction of pressure P1 while the proximalaortic portion 202 a includes a yarn reinforced sleeve configurationthat forecloses expansion of the proximal aortic portion 202 a untilpressure within the balloon 202 reaches a predetermined pressure P2.Moreover, the fibers are configured so as to mechanically limit theenlargement of the proximal aortic portion to a predetermined size andshape, namely a size shape that conforms the proximal aortic portion 202a to the aortic root sinuses. Hence, in operation, when pressure P1 isintroduced into the balloon 202, the LVOT segment 202 b expands into theLVOT in a compliant manner and thus anchors the catheter in the LVOT.Then, when pressure P2 is reached, the proximal aortic segment 202 aexpands in a manner to perform the valvuloplasty, the yarn of the sleevemechanically limiting the expansion (and thereby protecting the valve)to a predetermined shape and size.

In this regard, a taper zone 602 is designed into the balloon 200configuration discussed above between the proximal aortic portion 202 aand the LVOT segment 202 b. This taper zone 602 has a narrower diameterthan each of its adjacent sections and controls the medial “hip” shapeof the balloon that is used to seat the balloon within the annulus ofthe valve and prevent excessive loads from being exerted by the balloonon the annulus during inflation.

Further in this regard, the fiber reinforcement in this embodiment couldinclude polymeric yarns that are either fully oriented or partiallyoriented. Fully oriented yarns have characteristics that provide a highpressure mechanical “stop” and thus are particularly suited to creatingballoon shape. Partially oriented yarns (POY) are slightly morecompliant in the initial expansion stages and thus introduce a slight“stretch” characteristic into the expansion of the proximal aorticportion 202 a. However, as the POY fibers become drawn, they becomestronger. Therefore, the POY fibers can be configured on the proximalaortic portion 202 a such that the POY fibers reach this “stronger”state at the same time the proximal aortic portion 202 a reaches itsdesired size and shape and thereby mechanically limit further expansionof the proximal aortic portion 202 a.

In the embodiment using the fully oriented yarns, it is preferable touse a knit structure since the knit structure could inherently introducea degree of “stretchiness” into the sleeve that the fully oriented yarnsmay not otherwise provide. In the embodiment using the POY fibers, it ispreferable to use a braid or weave of about 100-200 denier polyesteryarns at 20-5-picks per inch for the braid embodiment and 40-6-picks perinch for the weave embodiment.

Referring to FIGS. 5G-51, in a second embodiment, the LVOT segment 202 bof the balloon 202 is fiber-reinforced such that it is eithernon-compliant or only partially compliant while the proximal aorticportion 202 a is fiber-reinforced such that it exhibits compliantcharacteristics but only after a threshold pressure is reached. Forexample, the LVOT segment 202 b may be comprised of a non-compliant orpartially compliant PET or nylon plastic material while the proximalaortic portion 202 a may be comprised of elastic filaments (e.g.,spandex) that are compliant only after a threshold pressure. As aresult, when pressure P1 is introduced into the balloon 202, the LVOTsegment will resist expansion or only slightly expand until a pressureP1 is achieved, at which point the LVOT segment 202 will expand to ashape constrained by its PET or nylon plastic construction and whichconforms to the LVOT. Then, when pressure increases to P2, the LVOTsegment 202 b will remain in its expanded state while proximal aorticportion 202 a begins to expand in a compliant way as governed by thecompliant properties of the elastic filaments. In other words, theelastic filaments hold or restrain the expansion of the proximal aorticportion 202 a until the LVOT segment 202 b expands and P2 is reached.Then the elastic filaments become loaded and start to stretch and expandin a compliant manner thereafter.

The elastic filaments in this second embodiment also create a texturedsurface that facilitates stability of the balloon 200 during thevalvuloplasty. Furthermore the elastic filaments greatly assist incompressing the proximal aortic portion 202 a to its initial uninflatedsized so as to also greatly assist removal of the catheter after thevalvuloplasty is complete.

In this second embodiment, the elastic filaments could comprise a braidof about 200 denier polyurethane filaments. In this regard, a braidedfabric of elastic filaments would facilitate a greater range ofexpansion capabilities for the proximal aortic portion 202 a. On theother hand, a woven fabric of elastic filaments would facilitate a morestable length expansion of the proximal aortic portion 202 a.Furthermore, it should be recognized that the arrangement and makeup ofthe elastic filaments used in the proximal aortic portion 202 a, e.g.,filament size, fabric density, yarn tension, can be used to control theoverall size and shape and inflation progression of the LVOT section 202b as well as the P2 activation pressure.

Referring to FIGS. 5J-5L, in a third embodiment, the balloon 200 may bea composite of a balloon membrane and a fabric with the fabric coveringessentially the entire balloon membrane. The makeup of the fabric wouldcontrol and govern the shape ultimately achieved by the balloon membraneand the makeup of the balloon membrane would control and govern theexpansion system of the fabric. More specifically, the fabric wouldinclude fibers that limit the expansion of the balloon to certainpredetermined shapes and sizes and the balloon membrane would includeeither different thicknesses or different material elasticity along itslength so that the LVOT portion 202 a expands prior to expansion of theproximal aortic properties 202 b.

In this regard, in a preferred embodiment the fabric could be comprisedof a 200-300 denier PET yarn that could be woven, knitted or braided andwherein the fibers are configured to control the expansion shape of thefabric. In a weave embodiment, the fabric is woven to match the expandedshapes as depicted in the Figures. In a braid embodiment, the fabricwould be made by changing the braid angles over a shaped mandrel.

Also in this embodiment, the balloon membrane could be comprised of onematerial (e.g., silicone, polyurethane or some other highly elasticpolymer) wherein the wall thickness at its LVOT portion is around 0.015to 0.02 inches and the wall thickness in the proximal aortic portion isabout 0.025 to 0.03 inches. Or in the alternative, the balloon membranecould be comprised of one material such as silicone but configure thesilicone such that it has a durometer of around 10-15 A at the LVOTportion and a durometer of around 15-25 A at the proximal aorticportion. In some applications, it is conceivable that a durometer ashigh as 60 A could be used. Although a material with a durometer of thismagnitude may be thick, it is conceivable that it could be used in avery thin cross section. In any event, a balloon membrane configuredusing this concept can control the preferential expansion of the LVOTsection before the proximal aortic portion. In one embodiment, there maybe no fabric at all and the expansion and shape characteristics of theballoon 200 are controlled by using different balloon materials,different balloon material hardnesses, and/or wall thicknesses to governthe expansion of the balloon.

With regard to the third embodiment of this section, a dual yarn systemfabric could be used to create a compliant balloon system. “Wrapped”yarns typically comprise a polyurethane filament, such as spandex, witha high wrap per inch of polyester wrapped around it. As the polyurethanefilament is stretched, the polyester yarns begin to unwraps or untwistsfrom around the polyurethane until the polyester yarn is in tension.When this happens, the polyester yarn becomes a limitation on furtherstretching of the polyurethane. A woven, braided, or knitted wrappedyarn system using this approach would create a highly stretchy fabricwith stretch limiting elements, namely, the polyester yarns. Changingthe yarn density, or size of the yarns in the fabric will govern theactivation pressures P1 and P2. Higher density fabric would require ahigher activation pressure.

With regard to the fiber reinforcement constructions discussed above andelsewhere in the specification, it is likely that braids and weaveswould be used although knits are possible as well. Braids and wavestypically lead to more stable fabrics than knits an thus are better ableto resist tension until a target pressure, e.g., P2, is reached, afterwhich they will stretch and allow expansion.

With further regard to the fiber reinforcement constructions discussedabove (and with regard to other embodiments of the present inventiondiscussed elsewhere), it is noted that the fiber reinforcement approachallows the sealed portion of the device (the part that receives andcontains the pressure for the purpose of expansion) can be very thinwalled compared to prior art balloons and still tolerate high pressures.With the above described embodiments (and others not specificallyidentified), the wall of the sealed chamber can be as thin as 0.002inches thick and can work in a pressure range of 2-20 atm.

It is also noted that the above embodiments (as well as otherembodiments discussed in this application) could be configured such thatthe balloon 200 is actually comprised of two separate balloons insteadof one balloon with two sections. In a two balloon embodiment, the samefiber reinforcement aspects discussed above could be used to achieve theexpansion, shape and size characteristics that optimize thevalvuloplasty being performed.

The distal anchoring section 202 b of catheter balloon 202 is shapedsimilarly to the distal anchoring balloon 104 in FIG. 1. In thisrespect, the distal anchoring section 202 b is located near the distalend of catheter body 204 and has a taper that increases in the axial,distal direction to closely conform to the LVOT 130. Note also thatmodification for the LVOT balloon 104 can be used for this distal LVOTsegment 202 b. The proximal aortic section 202 a is also shapedsimilarly to the aortic sinus balloon 102 in FIG. 1, preferablyconforming to the shape of the rounded aortic sinuses 123 when in aninflated state.

A long sheath 124 may be utilized for longitudinal stabilization of thecatheter balloon 202 during inflation by abutting and pressing againstthe catheter balloon 202 in a distal direction. Since the inflatedcatheter balloon 202 tends to act as a sail, catching the antegrade flowof pulsatile blood flow from the heart, the sheath 124 can provideadditional axial stability, reducing the tendency of the catheterballoon 202 to migrate.

In operation the single balloon catheter 200 is introduced through thefemoral or brachial artery using a Seldinger technique with a vascularsheath introducer and a guidewire. After placement of the guidewireacross the aortic valve, the single balloon catheter 200 is advancedretrograde over the guidewire such that the pigtail 206 is positioned inthe left ventricle. Next, the distal anchoring section 202 b ispositioned, using fluoroscopy in combination with radiopaque markers203, within the LVOT 130, just underneath the valve annulus 125. Thedistal anchoring section 202 b is inflated with liquid contrast mediawhich is communicated through an inflation port within the catheterballoon 202, best seen in FIG. 5A. The distal anchoring section 202 bexpands in diameter as inflation media is added, allowing it to pressagainst the walls of the LVOT 130, thus longitudinally securing theposition of the single balloon catheter 200. Once the distal anchoringballoon 202 b is anchored securely within the LVOT 130, the proximalaortic section 202 a is inflated by further increasing pressure withinballoon 202, as seen in FIGS. 5B and 5C. It may be necessary to inflatethe proximal aortic section 202 a several times and at several gradeddiameters to achieve improved valve leaflet 126 flexibility and thedesired pressure gradient reduction.

Alternatively, the single balloon catheter 200 may use a rapid exchangestructure (not shown) having a guide wire which is generally locatedoutside the catheter body 204. A portion of the guide wire passesthrough a short distal lumen (e.g. about 40 to 50 mm in length) locatedwithin the catheter body 204, distal to the catheter balloon 202. Thus,during a valvuloplasty procedure, the guide wire lies predominantlyalong side the catheter balloon 202 and catheter body 204 within thevessel except at the distal end of the single balloon catheter. Thisrapid exchange wire compressed between the balloon and vascularstructures provides additional traction and stability to the catheterballoon 202 during expansion. Additionally, the catheter body 204 mayhave a lower profile since a guide wire lumen throughout the catheterbody 204 is not needed.

FIGS. 11A and 11B illustrate yet another variation on the abovedescribed preferred embodiments, having two longitudinal and parallelcatheter balloons 332 and 339. The overall inflated shape of the duallongitudinal balloon catheter 330 is similar to previously describedembodiments, having a distal anchoring portion with an increasing taperin the distal direction for LVOT fixation and a rounded proximal portionfor aortic valve dilation. Media ports 336 and 338 supply the inflationmedia to each catheter balloon 332, 339, while radiopaque markers 334are used as references when positioning the dual balloon catheter 330.The dual catheter balloons 332, 339 may be inflated in a sequentialmanner. Sequential balloon inflation allows some antegrade blood flowwith inflation of catheter balloon 332 and therefore less distalmigration during the initial phase of inflation. Also, the inflatedbi-lobed configuration can achieve more radial stretching of theleaflets in its greatest diameter. Also blood flow would be permitted inthe recesses of both lobes of catheter balloons 332, 339 when inflated.Multiple sequential inflations can be carried out using radiopaquemarkers 334 to achieve different radial orientations to further improvevalve leaflet flexibility and pressure gradient reduction.

As with the previous embodiment, the dual catheter balloons 332, 339have differing compliance along their length, creating the overallinflated shape seen in FIG. 1 1A. As described above, the differingcompliance is preferably achieved with fiber based membranes.

Referring now to FIGS. 12A-12C, a single umbrella balloon catheter 340is shown, having a modified catheter balloon 342 shape. Single umbrellaballoon catheter 340 is similar to the above described single ballooncatheter 200 embodiment, except for the overall shape of catheterballoon 342.

As with the previously described embodiment, the differing shape ofcatheter balloon 342 is preferably controlled with fiber based membraneswhich allow for varying compliance of different portions of the catheterballoon. In the present preferred embodiment, the distal anchoringsection 342 b utilizes the fiber based membranes to create a curved“upside-down umbrella” shape, preferably about 6 mm in length with adistal to proximal taper ranging between about 14 mm to about 22-24 mmin diameter. The proximal aortic section 342 a of balloon 342 isresponsible for valve dilation and has an increasing taper in the distaldirection of the catheter 340. The maximum inflated diameter ispreferably about 24 mm to 30 mm toward the midsection. The LVOT sectionrequires less media to fill, thus it will fill faster, allowing the armsof the distal anchoring section 342 b to lock underneath the annulus 125in the recess between the annulus 125 and the boundary of the adjacentLVOT.

FIGS. 13A and 13B illustrate broad wing catheter 350, similar to theprevious embodiment except for a broader, wing-shape of the distalanchoring section 352 a. This broader wing shape of the distal anchoringsection 352 a reduces the likely hood of migration in the antegradedirection while the proximal aortic section 352 b is being inflated. Inaddition, there remains a potential space 127 between the distalanchoring section 352 a and the inflated proximal aortic section 352 bwhich further reduces antegrade migration when segment 352 b isinflated.

Balloon Catheter With Perfusion Channel

Turning to FIG. 8, yet another preferred balloon catheter 300 embodimentis shown, having a center perfusion channel 302 a and possibly a one-wayperfusion valve 304 at the proximal end of the center perfusion channel.

As with previously described embodiments, the catheter balloon 302 has asingle chamber (or alternatively may have multiple balloon chambers),with a tapered distal region for engaging the LVOT and a roundedproximal region for expanding against valve leaflets 126 (not shown inFIG. 8). The catheter balloon 302 has varying compliance, as describedwith previous embodiments, to allow the distal region to expand firstagainst the walls of the LVOT, locking the balloon catheter 300 inplace. This is followed by expansion of the less compliant proximalregion which conforms to the aortic sinuses 125 (not shown in FIG. 8),pressing against the valve leaflets 126.

The catheter balloon 302 is fixed to a multi-lumen catheter body in anoff-center manner, as seen best in FIG. 8. With inflation of thecatheter balloon 302 and expansion within the aortic root and LVOT,longitudinal movement is reduced by allowing perfusion through thecentral channel 302 a.

The center channel 302 a of catheter balloon 302 allows blood to perfusedistally through the catheter 300, thus increasing the amount of timethe catheter balloon can be inflated without causing significant bloodflow compromise. In addition, the central perfusion lumen improveslongitudinal stability of the catheter balloon 302 position by allowingfor a low resistance pathway for antegrade blood flow. To preventback-flow of blood, a one-way valve 304 may be located at the proximalend of the perfusion channel 302 a.

Alternatively, the one-way valve 304 can be located within the center ofperfusion channel 302 a, the distal end, or anywhere in between.Further, a one-way valve 304 may not be used in such an embodiment, asseen in the perfusion catheter 310 of FIG. 9. This perfusion catheter310 similarly has a single channel 312 a within the catheter balloon312.

In yet a further alternative, the catheter balloon perfusion catheter310 of FIG. 9 could be modified such that the catheter balloon 312 nolonger has a LVOT distal portion or it has a truncated LVOT distalportion as shown in FIGS. 9A and 9B. In this embodiment, the balloon ofthe perfusion catheter 310 takes on more of a “donut” appearance.

As seen in FIG. 22, a balloon perfusion catheter 510 may include an offaxis perfusion channel 514, having an opened side 514 a extending alongthe periphery of the anchoring section 512 b and another opening at theproximal aortic section 512 a. The perfusion channel 514 is positionedperipherally at the distal end of catheter balloon 510 b, but is locatedcentrally in the proximal aortic section 512 b. Such an off axisperfusion channel 514 readily allows antegrade blood flow during bothphases of balloon inflation, as indicated by the arrows seen in FIG. 22.

Referring now to FIGS. 10A and 10B, a similar single balloon catheter320 is illustrated, having two or more side perfusion channels 322 aalong the periphery of the catheter balloon 322, instead of a singlecenter channel. As with the previously described single chamber ballooncatheters, this balloon catheter 320 is variably compliant to allow forinitial expansion of the distal portion of balloon 322 to anchor withinthe LVOT. Further, the variable compliance assists in the creation ofthe perfusion channels 322 a when the catheter balloon 302 is inflated.The perfusion channels 322 a are less compliant than the other regionsof the catheter balloon 322, which prevents the perfusion channels 322 afrom expanding outward in the same manner as the other regions ofcatheter balloon 322.

Additionally, the catheter balloon 322 may include internal supports(not shown) that maintain the inwardly angled shape of the perfusionchannels 322 a. For example, additional material within the catheterballoon 322 may secure portions of the perfusion channels 322 a to thecatheter body, preventing the perfusion channels 322 a from expandingoutward. Radiopaque markers 324 may be positioned on the outer radius ofthe catheter balloon 322 for reference markers, assisting a user withcatheter positioning during a procedure, permitting, for example,multiple balloon inflations through a series of about 45 to 90 degreerotations. This would reduce the likelihood of creating gaps whereportions of valve leaflets could migrate and therefore not be renderedmore flexible.

As seen in FIG. 10 b, the perfusion channels may include a membrane 321,covering the length of the perfusion channels 322 a, yet leaving bothdistal and proximal perfusion channel 322 a ends open. Thus, theperfusion channels 322 a and membranes 321 form tube-like structures,providing greater structural support to the perfusion channels 322 a yetstill allowing perfusion. Membrane 321 additionally prevents gaps wherethe inflated balloon would otherwise not come in contact with the valveleaflets 126. Note the rounded and non-eccentric configuration of thecatheter tip 323 which can be placed on balloon valvuloplasty cathetersthat need to be rotated through out a 360 degree arc during multipleinflation. This decreases the likelihood of resistence to rotationcreated by the previously noted pigtail configurations.

FIGS. 21A-21D illustrate an enhanced catheter 500 design similar to thatshown in FIGS. 10A and 10B. However, the enhanced catheter 500 includesa single catheter balloon 502 having perfusion channels 502 c along themargins of the distal anchoring section 502 b only and specifically donot extend across the aortic segment 502 a. As with previousembodiments, the distal anchoring section 502 b inflates first,expanding against the LVOT. The perfusion channels 502 c are inwardlycurved longitudinal conduits which allow blood to flow around theanchoring section 502 b during a procedure. The perfusion channels 502 cmay be enclosed by a membrane 501, as seen in FIG. 21B. The membrane 501forms longitudinal tubes which can have a single channel or multiplechannels, with an overall linear or spiral shape.

With reference to FIGS. 21E-21K, yet further embodiments of a catheterdesign having perfusion channels is disclosed. In this regard, theseembodiments are especially suited to the balloons using fiberreinforcement to control expansion and shape characteristics of thecatheter (e.g., the embodiments of FIGS. 5A-5L). Referring to FIG. 21E,a balloon 202 may be configured to have a strap 604 that connectsinternally across opposing internal surfaces of the balloon 202. Thestrap 604 is in tension and thus constrains the opposing surfaces of theballoon from fully expanding. As a result, perfusion channels 606 arecreated by the balloon 202 within the body lumen 602 where the device isplaced.

Referring to FIG. 21F, the balloon 202 could be fabricated such thatfiber reinforcement of the balloon requires the balloon 202 to take on anon round shape (e.g., a star shape, a triangular shape or a squareshape) when inflated. This too results in the formation of perfusionchannels 606.

Referring to FIG. 21G and 21H, the balloon 202 could be configured witha strap or straps 604 that are adhered to the external surface of theballoon 202. Furthermore the straps 604 would constrain the expansion ofthe balloon 202 such that the balloon “buckles” at certain locations atcertain pressures. This “buckling” would lead to “buckle zones” 608 thatalso would serve to create perfusion channels 606. In this regard, FIG.21H depicts a strap as it would surround the proximal section 202 b andas a strap would surround the distal section 202 a of the balloon 202 tocreate the aforesaid “buckle zones.”

FIGS. 21I-21K depict an embodiment wherein the distal end 609 theproximal section 202 b and the distal end 611 of the distal segment 202a of the balloon 202 are each movable relative to the proximal end 607of the proximal section 202 b and the proximal end 609 of the distalsegment 202 a, respectively. Alternatively, each section of the ballooncould be a separate balloon wherein the distal end of each balloon ismovable along the catheter shaft. Furthermore, a plurality of straps 604extend from the proximal to distal end of each balloon segment and eachend of each strap is connected to the catheter shaft.

Hence, when, for example, the distal segment 202 a of the balloon 202begins to expand, the distal end 611 of the distal segment 202 a willbegin to move toward the proximal end of the catheter. This will allowthe distal segment 202 a to begin to increase in diameter while becomingshorter in length. However, the presence of each strap 604 willconstrain the increasing size of the distal segment 202 a in a way asshown in FIG. 21J such that perfusion channels 606 are created.Similarly, as shown in FIG. 21K, as the proximal segment 202 b inflates,it too will be constrained by the straps 604 so that the proximalsegment 202 also is forced to create perfusion channels 606.

In a preferred embodiment, the straps discussed above would be made froma thin wall woven polyester fabric. It would be a band of around 60Denier by around 2 mm.

Ring and Balloon Catheter

FIGS. 6A-6C illustrate yet another preferred embodiment of the presentinvention, this embodiment including a ring and balloon catheter system250 for creating multiple flexible hinge points in the valve leaflets126. The ring and balloon catheter 250 acts to “pinch” the valveleaflets 126 between an expandable ring 254 and a balloon 258.

The expandable ring 254 is self expanding, being controlled with ringarms 256 fixed to the circumference of the ring 254. The ring arms 256are slidably positioned within a lumen of the catheter sheath 252 andextend out of the distal end of the sheath 252 through movement of thecontrol lever (not shown), allowing a user to push the ring 254 awayfrom the catheter body 252. In a retracted state, the ring arms 256maintain the diameter of the ring 254 at a minimum size. When the ringarms 256 push the ring 254 in a distal direction, the diameter of thering 254 expands.

A catheter balloon 258 is in communication with a media inflation lumen.The balloon catheter 258 operates independent of the sheath 252 and itsadvanceable ring 254. In other words, the ring 254 with its ring arms256 can be advanced and retracted independently of advancement andretraction of the balloon catheter 250. The balloon is elongated inshape when inflated, expanding within, and pressing the valve leafletsagainst the inside of ring 254. Preferably, the catheter balloon 258 hasan inflated diameter no greater than about 1-2 mm's larger than the ringto prevent avulsion of the leaflets 126.

In operation, the user positions the distal end of the catheter 250within the aorta 128 just above the aortic valve leaflets 126. Next, thering arms 256 are deployed outward in a distal direction from thecatheter sheath 252, causing the ring 254 to expand. The user positionsthe expanded ring 254 on the aortic surface of the valve leaflets 126.Next, balloon catheter 250 is advanced and balloon 258 positioned withinboth leaflets 126 and ring 254. Media is then injected through a medialumen within the catheter body 250 to inflate catheter balloon 258. Asthe catheter balloon 258 expands, it presses against the ring 254 andleaflets 126, pinching and bending the leaflets 126 to create a hingepoint 126 a, as shown in FIG. 6C. The formation of these hinge pointsallows for more broad leaflet opening and thus better passage of bloodthrough the valve. This procedure may be performed multiple times withdifferent ring diameters to create multiple hinge points 126 a on thevalve leaflets 126. When finished, the user merely deflates the catheterballoon 258 and retracts balloon catheter 250 into the sheath 252. Ringarms 256 are then retracted within the delivery sheath 252, which issubsequently then removed from the patient.

In addition, the expandable ring 254 may be mounted with tiny aperturesalong its internal circumference which can be used to infuse locallydelivered drugs, for example, anti-restenotic drugs into the aorticsurfaces of the valve leaflets 126 pinched between the ring 254 andinflated catheter balloon 258. The ring lumen may be connected to aninfusion port at the proximal end of the sheath and may extend thelength of the sheath within one or more of the ring arms 256.

Balloon Catheter With Wires

Referring now to FIGS. 7A and 7B, another preferred embodiment of thepresent invention is illustrated, having three longitudinal wires 272(although they can occur in any number, including 2 or more than 3)which are expanded with balloon 274 inflation to anchor and preventballoon slippage across the aortic valve. The tripod wire catheter 270contains a catheter balloon 274 which expands underneath thelongitudinal wires 272, pushing them outwards preferably, although notnecessarily, into the commissures of the valve. The balloon 274 can besimply fusiform in shape or be configured with multiple segments asdescribed for the embodiments previously discussed.

The three longitudinal wires 272 are fixed to two wire mounting rings278, one or the other of which is secured to the catheter body 276, forexample the proximal ring 278 a. The nonfixed wire mounting ring 278 bcan slide along the catheter body 276, allowing the longitudinal wires272, which are not along their length attached to the balloon surface,to bow outwards or lie flat against the catheter body 276. Positionedunderneath the longitudinal wires 272 is a catheter balloon 274 whichcommunicates with an inflation media lumen within the catheter body 276.

In operation, the tripod wire catheter 270 is positioned across theaortic valve leaflets 126. Next, the catheter balloon 274 is inflated,expanding against both the longitudinal wires 272 and the leaflets ofthe valves. As the catheter balloon 274 presses against the longitudinalwires 272, the wires 272 expand out with at least part of the balloon274 conforming to the aortic sinuses and adjacent LVOT, creating pointsof increased friction between the balloon 274 and leaflets 126, thatprevent slippage. Additionally, these longitudinal wires 272 concentratelines of force to enhance fracturing of the calcified leaflets andpossibly separate occasionally fused commissures.

Petal Anchoring Catheter

FIGS. 14A and 14B illustrate yet another preferred embodiment of thepresent invention, this embodiment including petal anchoring catheter370, having expandable anchoring petals 374 which expand against theaortic root walls 128, laterally and inferiorly in the inferior recessesof the aortic valve sinuses. This will stabilize and prevent movement ofthe petal anchoring catheter 370 before and during balloon inflation.Once anchored, the catheter balloon 376 inflates to push the valveleaflets 126 against the anchoring petals 374 and adjacent the aorticroot walls 123.

The expandable anchoring petals 374 are preferably composed of nitinol,pre-set to expand to an open position. Each anchoring petal 374 has aradiopaque marker 378 at its end for reference when positioning thepetal anchoring catheter 370. The expandable anchoring petals 374 arepacked within a sheath (not shown) while being advanced through apatient's vascular system.

Since the anchoring petals 374 have a basic wire-frame structure, theypermit simultaneous catheter 372 fixation and perfusion while balloon376 is uninflated. This allows the petal anchoring catheter 370 to beleft in place for extended periods of time. Further, the catheterballoon 376 may have perfusion conduits previously described in thisapplication to allow for additional perfusion during balloon inflation.

The anchoring petals 374 may be fixed at a specific length away from thecatheter balloon 376 or may be decoupled to allow for additionaladjustment during a valvuloplasty procedure. To reduce aortic roottrauma, the anchoring petals 374 are preferably somewhat flexible,allowing for a “soft” engagement with the aortic root wall 123.

In operation, the petal anchoring catheter 370 is positioned so that thecatheter balloon 376 passes through the aortic valve. Next, theanchoring petals 374 are deployed, engaging the aortic root wall 123 andthe inferior recesses of the aortic sinuses near the annulus 125,preventing the petal anchoring catheter 370 from longitudinal movement.Finally, the catheter balloon 376 is inflated so as to push open thevalve leaflets 126. The catheter balloon 376 is then deflated but may bereinflated multiple times to achieve a desired leaflet flexibility andpressure gradient reduction. When this has been achieved, the anchoringpetals 374 are retracted and the petal anchoring catheter 370 is removedfrom the patient.

In an alternative preferred embodiment shown in FIGS. 15A-15C, a petalanchoring catheter 360 similar to the previously described embodiment isshown having stress risers 364 along the wires of anchoring petals 362.These stress risers 364 allow multiple hinge points to be created alongthe valve leaflet 126.

During a valvuloplasty procedure, the petal anchoring catheter 360 ispositioned within an aortic root 123 and the anchoring petals 362 aredeployed in the aortic root 123 immediately proximal to the valveleaflets 126. Next, the catheter balloon is inflated, expanding thevalve leaflets 126 against the anchoring petals 362 and the stressrisers 364, best seen in FIG. 15B. The stress risers 364 create pointsof stress concentration behind the leaflets 126, allowing for multiplehinges in the leaflets 126 to be more easily created to further enhancedleaflet flexibility.

It should be noted that the petal anchoring catheter 370 of FIG. 14A and14B may be additionally used to hold a valve open for other proceduresor create points of friction between the balloon 376 and the leaflets126 to prevent slippage. In this manner, the anchoring petals 374 arepositioned along the ventricular surface of the valve leaflets 126 andexpanded with balloon 276 inflation, pressing the leaflets 126 into theaortic root sinuses. Additionally, the petal anchoring catheter 360 and370 may be used as a fixed platform on which prosthetic implants can bedelivered to and deployed on the aortic valve.

Mesh Anchoring Ring

Turning now to FIGS. 23A-23C, a balloon catheter 550 is illustratedaccording to the present invention, having an expandable mesh anchoringdisk 556. As with many of the previously described embodiments, theballoon catheter 550 anchors within the LVOT when the mesh anchoringdisk 556 expands to press against the walls of the LVOT.

The mesh anchoring disk 556 is expandable and preferably made from aplurality of semi-rigid, elongated elements which form a mesh. The meshanchoring disk 556 may be expanded by a trigger wire or cable (notshown) which moves either the distal or proximal end of the meshanchoring disk 556 relative to the opposing end, thus expanding orcontracting the shape. Since the mesh anchoring disk 556 is composed ofa mesh-like material, blood is able to perfuse through.

In operation, catheter 550 is advance over a guide wire through avascular introductory sheath. The user utilizes radiopaque markers 554to position the balloon catheter 550 as previously described in thisapplication. Once the mesh anchoring disk 556 is positioned at the LVOT,the user anchors the balloon catheter 550 by expanding, i.e. activatingthe mesh anchoring disk 556, engaging the wall of the LVOT. The catheterballoon 552 is then inflated a desired amount to open the valve leaflets126. Next, the catheter balloon 552 is deflated and the mesh anchoringdisk 556 is contracted, i.e. inactivated, allowing the balloon catheter550 to be removed from the patient.

Alternately, the mesh anchoring disk 556 may be self expanding and mayoptionally have compliant apices to prevent injury to the aortic valve.The balloon catheter 550 may be further used as a fixed platform onwhich prosthetic implants can be delivered to and deployed on oradjacent to the aortic valve. These prosthetic implants may includeprosthetic valves, drug eluting or similar devices. In addition, thisfixed platform can be used to deliver and position high energy sourcesfor debulking valve leaflets such as excimer lasers, high energy lowfrequency ultrasound and radio frequency.

Drug Delivery Devices

The valvuloplasty procedures described in this application generallyinvolve the application of significant amounts of force on the aorticvalve leaflets. It is well known in the art that such force and/orsimilar trauma can cause restenosis of the valve, leaving the valveleaflets again stiff and inflexible. In this manner, eventual loss ofthe improved valve opening occurs with return of the initialtransvalvular pressure gradient.

To this end, it is desired to deliver drugs, temporarily positionbrachytherapy sources, or other locally delivered therapeutic substancesto the aortic valve to prevent or moderate aortic valve restenosis oreven progressive stenosis. One method of delivering such drugs is by wayof a local drug eluting implant.

For example, a drug eluting implant may deliver paclitaxel or any othertaxane/taxane derivate, rapamycine, or a rapamycin derivative,flurouracil, other pharmacological agents, anti-mitotics,anti-proliferatives, proteins, genes, gene therapy vectors,RNA/nucleotides or any other agent that prevents the valvular restenosisprocess. Further, such a device may elude decalcification agents as wellas agents to limit or reverse collagen deposition and in this mannercause favorable remodeling of the valve leaflets and thereby reversestenosis. Such devices may also eliminatethrombus/inflammation/calcification.

Turning to FIG. 16, a flexible finger implant 400 is shown having ananchoring ring 402 and a plurality of drug eluting fingers 404. Theanchoring ring 402 seats within the LVOT adjacent to the valve annulus125 with the drug eluting fingers 404 angled towards the valve leaflets126. The drug eluting fingers 404 contact the valve leaflets 126,eluting a desired anti-restenosis drug or substances as listed above.The flexible finger implant 400 may be delivered by the valvuloplastycatheter embodiments described in this application, modified to includeimplant delivering mechanisms, or a separate implant delivery cathetermay be used.

FIGS. 17A and 17B illustrate another embodiment of an implant 410 whichincludes an anchoring ring 411 and T-shaped drug eluting pods 412. Theanchoring ring 411 engages the LVOT adjacent to the valve annulus 125while the T-shaped drug eluting pods 412 are fixed to the anchoring ring411 and pass proximally through the commissures of the valve, allowingthe elongated horizontal portion of the T-shaped drug eluting pods 412to contact the aortic side of each leaflet 126 base. By contacting thevalve leaflets 126, the T-shaped drug eluting pods 412 are able totransfer in a time dependent manner, anti-restenosis drugs to theleaflets 126. The horizontal arms of the T shaped pods 412 pinch thevalve leaflets between these extensions and the ring on the LVOT side,helping to preserve a stable position to prevent dislodgment. TheT-shaped pod implant 410 may be delivered by the valvuloplasty catheterembodiments described in this application, modified to include implantdelivering mechanisms, or a separate implant delivery catheter may beused.

Note that variations on the T-shaped pod implant 410 are possible, suchas the L-shaped pod implant 414 seen in FIG. 18, having L-shaped drugeluting pods 416 which pass through the commissures of the valve tocontact the leaflet 126 base. Further, finger extensions such as theseseen on the device in FIG. 16, can extend from either the ring 411 orthe T shaped pods 412, to increase the surface area from whichadditional drugs can be delivered.

In yet another preferred drug eluting embodiment, FIG. 19 illustratesdrug eluting posts 420 having single or dual barbs. A puncture ormultiple punctures are preferably created in each valve leaflet 126 byway of radio frequency, laser, high energy low frequency ultra sound, orother devices to allow the drug eluting post to be easily pushed intothe valve leaflets 126. The barbs on one or both ends of the drugeluting posts 420 prevent the drug eluting posts 420 from sliding out ofthe apertures within the leaflets 126.

FIGS. 20A-20C illustrate yet another preferred embodiment of a drugeluting membrane 430 which is shaped to cover each valve leaflet 126 andis secured in place with a locking stud 432. A puncture or punctures arepreferably created in each valve leaflet 126 by way of radio frequency,laser, high energy low frequency ultra sound, or other device to allowthe locking stud 432 (which may or may not itself elude drugs) to beeasily pushed into. The locking stud 432, fixed to the drug elutingmembrane 430, is pushed through the leaflet 126 hole, securing the drugeluting membrane 430 to the leaflet 126. Further, high pressure infusionports could be added to any of the proposed or other embodiments inwhich anti-restenotic drugs or related substances could be infused intothe adjacent aortic valve. The membrane could be fabricated according tothe nanofiber process disclosed in U.S. application Ser. No. 10/314,086filed Dec. 6, 2002 entitled Covering And Method Of Using ElectrospinningOf Very Small Fibers, the contents of which are incorporated byreference.

Optionally, the above described drug eluting devices may be composed ofa bioabsorbable material which allows the device to be absorbed overtime. Additionally, the drug eluting devices may be composed of a metalor polymer mesh which allows cells to infiltrate and colonize, allowingthe mesh to become a “living structure”.

Although the invention has been described in terms of particularembodiments and applications, one of ordinary skill in the art, in lightof this teaching, can generate additional embodiments and modificationswithout departing from the spirit of or exceeding the scope of theclaimed invention. For example, although the application emphasizes theinvention as it may be utilized in performing aortic valvuloplasty, itshould be understood that the invention as disclosed and contemplated bythe inventors has far greater applicability and utility valvuloplastyalone. For example, the invention has applicability in various vascularapplications and other restrictions in the vascular system (e.g., venousvalves, other heart valves, urinary tract constrictions, coronaryrestrictions, etc.). Accordingly, it is to be understood that thedrawings and descriptions herein are proffered by way of example tofacilitate comprehension of the invention and should not be construed tolimit the scope thereof.

1. A device for performing valvuloplasty comprising: a catheter having alumen for transferring a media therethrough; a first expandable memberdisposed towards a distal end of said catheter; said expandable memberin fluid communication with said lumen; and, said first expandablemember having at least a first portion sized and shaped to be expandableto a profile substantially matching a profile of aortic root sinuses ofan aorta connected to a heart.
 2. The device of claim 1, wherein saidfirst expandable member further includes a second portion located distalto said first portion, said second portion being sized and shaped toexpand to a profile substantially matching a profile of a leftventricular outflow tract of said heart, and wherein said second portionexpands at a first media pressure, and said first portion expands at asecond media pressure.
 3. The device of claim 2, wherein said firstexpandable member is sized and shaped such that said first mediapressure is lower than said second media pressure such that said secondportion expands prior to said first portion.
 4. The device of claim 1,wherein said first expandable member is comprised of a variablycompliant material so as to ensure expansion of said first portion intosaid profile substantially matching a profile of said aortic rootsinuses.
 5. The device of claim 1, wherein said catheter includesradiopaque markers.
 6. The device of claim 1, wherein said lumenincludes a port opening within said first expandable member.
 7. Thedevice of claim 1, wherein said catheter includes a screen deployableproximal to said first expandable member.
 8. The device of claim 1wherein said catheter includes a second expandable member disposeddistal to said first expandable member, said second expandable memberbeing sized and shaped to expand into a profile that substantiallymatches a profile of a left ventricular outflow tract of said heart. 9.The device of claim 1, wherein a perfusion passageway is disposed withinsaid first expandable member.
 10. The device of claim 1, wherein saidexpandable member includes axially aligned perfusion grooves.
 11. Thedevice according to claim 9, wherein said perfusion passageway extendsthrough a longitudinal length of said first expandable member.
 12. Thedevice according to claim 11, wherein said perfusion channel includes avalve to control perfusion through said perfusion channel.
 13. Thedevice according to claim 9, wherein said perfusion passageway iscomprised of at least one channel disposed at a side of said firstexpandable member.
 14. The device according to claim 13, wherein saidperfusion passageway is comprised of two channels disposed at oppositesides of said first expandable member.
 15. The device according to claim8, wherein said first expandable member includes at least one perfusionchannel.
 16. The device according to claim 15, wherein said at least oneperfusion channel is comprised of two walls of said first expandablemember spanned by a membrane connecting said two walls.
 17. The deviceaccording to claim 9, wherein said perfusion passageway extends off-axisthrough said first expandable member.
 18. The device according to claim17, wherein said perfusion passageway includes an open channel disposedin a second portion of said expandable member, said second portion beingdistal to said at least a first portion.
 19. The device according toclaim 18, wherein said perfusion passageway includes a tubular channelabove said open channel.
 20. A method of performing aortic valvuloplastycomprising: providing a catheter having an expandable member; advancingsaid catheter towards an aortic valve; securing said catheter in place;and, urging leaflets of said aortic valve into an open state byexpanding at least a first portion of said expandable member to aprofile that substantially matches a profile of the aortic root sinusesof an aorta.
 21. A method as set forth in claim 20, wherein securingsaid catheter in place includes expanding at least a second portion ofsaid expandable member against the walls of a left ventricular outflowtract associated with said aortic valve.
 22. A method as set forth inclaim 20, wherein said providing of a catheter includes providing acatheter having an expandable member that also includes a secondportion, and wherein said securing of said catheter includes expandingsaid second portion against the walls of a left ventricular outflowtract associated with said aortic valve.
 23. A method as set forth inclaim 22, wherein the expanding of said first portion occurs after theexpanding said second portion.
 24. A method as set forth in claim 20,further comprising, allowing perfusion of blood past said expandablemember during and after the securing of said catheter in place.
 25. Amethod as set forth in claim 20, further comprising measuring a pressureproximal and distal to said aortic valve.
 26. A method as set forth inclaim 20, further comprising depositing an anti-restenosis agent in aregion of said aortic valve.
 27. The method according to claim 20,further comprising: providing a sheath movable over said catheter suchthat movement of said sheath controls exposure of said expandablemember; and, stabilizing said expandable member with said sheath afterexpanding said expandable member.
 28. A device for treating a heartvalve comprising: a sheath; a ring; said ring being movable between acompressed state within said sheath and an expanded state outside ofsaid sheath; said ring being sized to receive at least a portion of eachleaflet of said heart valve; an expandable member movable between afirst position within said sheath and a second position outside of saidsheath and within said ring; and said expandable member being sized andshaped to pinch said leaflets against said ring when said expandablemember is in an expanded state.
 29. The device according to claim 28,wherein said ring and said expandable member are sized and shaped suchthat hinge points are created on said leaflets when said expandablemember pinches said leaflets against said ring.
 30. The device accordingto claim 28, wherein said expandable member is a balloon.
 31. The deviceaccording to claim 28, further comprising at least one additional ring;said ring being interchangeable with said ring; said additional ringbeing of a different size than said ring.
 32. The device according toclaim 28, wherein said ring is attached to a control rod movablydisposed with said sheath.
 33. A method of treating of heart valvecomprising: identifying a diseased heart valve having calcified leafletsplacing a ring member against said leaflets; and, pinching said leafletsagainst said ring member so as to create a hinge region on at least oneleaflet removing said ring member.
 34. The method as set forth in claim33, wherein said pinching includes introducing an expandable member intosaid ring such that said leaflets are captured between said ring andsaid expandable member; and expanding said expandable member.
 35. Themethod as set forth in claim 33, further comprising placing a secondring against said leaflets and pinching said leaflets against saidsecond ring so as to form multiple hinge regions on said leaflets.
 36. Adevice for treating a heart valve comprising: a sheath; a cathetermovably disposed within said sheath; an expandable member disposedtowards a distal end of said catheter; a plurality of wires disposedadjacent said expandable member, said wires extending substantially thelength of said expandable member; and, said wires contacting said heartvalve when said expandable member is in an expanded state.
 37. Thedevice according to claim 36, wherein said plurality of wires are fixedat a distal end of said catheter and are movable relative to saidcatheter at a proximal end.
 38. The device according to claim 36,wherein said plurality of wires comprises three wires evenly spaced fromeach other around said expandable member.
 39. The device according toclaim 36, wherein said expandable member is a balloon member.
 40. Amethod of treating a heart valve comprising: identifying a diseasedvalve having stenosis; delivering an expandable member to said diseasedvalve; expanding said expandable member against leaflets of saidstenosed valve; and, substantially preventing slippage of saidexpandable member by urging a plurality of wires against said diseasedvalve during the expanding of said expandable member.
 41. A method asset forth in claim 40, wherein said urging of said plurality of wiresincludes urging there wires equally spaced around the circumference ofsaid expandable member.
 42. A method as set forth in claim 40, whereinsaid expanding of said expandable member includes expanding a balloonmember.
 43. A method as set forth in claim 40, further comprising,urging said plurality of wires against said leaflets such that each ofsaid wires create a focal point of force concentration against saidleaflets.
 44. A method as set forth in claim 43, wherein said urging ofsaid plurality of wires against said leaflets introduces greaterflexibility into said leaflets.
 45. A method as set forth in claim 43,wherein said urging of said plurality of wires against said leafletscauses separation of at least one point of commissural fusion of saidleaflets.
 46. A device for treating a heart valve comprising: a tube; afirst expandable member disposed toward a distal end of said tube; asecond expandable member disposed toward a distal end of said tube andbeing laterally adjacent said first expandable member; a first inflationmedia port disposed within said tube and communicating with said firstexpandable member; and, a second inflation media port disposed withinsaid tube and communicating with said second expandable member.
 47. Adevice according to claim 46, wherein said first and second expandablemembers collectively form a first portion that substantially conforms tothe shape of a left ventricular outflow tract of a heart when said firstand second expandable members are each in an expanded condition.
 48. Amethod of treating a heart valve comprising: identifying a diseasedvalve having calcified leaflets; interposing an expandable memberagainst said leaflets; radially expanding a first side of saidexpandable member; and, radially expanding a second side of saidexpandable member in substantially the same longitudinal region as theradially expanded first side of said expandable member.
 49. A methodaccording to claim 48, further comprising expanding an upper region ofsaid expandable member following radially expanding both the first andsecond side of said expandable member.
 50. A method according to claim49, wherein the expanding of said upper region includes expanding saidupper region so that it substantially conforms to a profile of aorticroot sinuses of an aorta proximal to said heart valve.
 51. A device forperforming valvuloplasty in an aorta comprising: a catheter having alumen for transferring a media therethrough; a first expandable memberdisposed towards a distal end of said catheter; said expandable memberin fluid communication with said lumen; and said first expandable memberhaving a first portion sized and shaped to be expandable to a conicprofile having a section that substantially presses against an areaimmediately distal to an aortic valve when said first expandable memberis in its expanded state.
 52. A device according to claim 51, whereinsaid first expandable member includes a second portion disposed proximalto said first portion; said second portion sized and shaped so as topush leaflets of said aortic valve towards an aortic wall when saidsecond portion is in an expanded state.
 53. A device according to claim52, wherein said second portion is sized and shaped so as to pushleaflets into the aortic root sinuses of said aorta.
 54. A deviceaccording to claim 52, wherein said expandable member is a balloon. 55.A device according to claim 54, wherein said expandable member is avariably compliant balloon such that expansion of said first portionoccurs before expansion of said second portion.
 56. A method of treatinga heart valve comprising: identifying a target heart valve havingdiseased leaflets; delivering an expandable member at said diseasedleaflets; and, engaging a lower conical portion of said expandablemember against an underside of said leaflets so as to thereby securesaid expandable member in place.
 57. A method according to claim 56,further comprising expanding a higher portion of said expandable memberagainst said leaflets and thereby pushing said leaflets against a wallof said aorta.
 58. A method according to claim 57, wherein the expandingof said higher portion includes pushing said leaflets into the aorticroot sinuses of said aorta.
 59. A method according to claim 57, whereinsaid engaging of said lower conical portion and said expanding of ahigher portion leads to treatment of said heart valve.
 60. A device forperforming valvuloplasty in an aorta comprising: a sheath; a cathetermovably disposed within said sheath, said catheter having a lumen fortransferring a media therethrough; at least one arm member sized andshaped to deploy from said sheath and engage an aortic sinus wall; and,an expandable member attached to said catheter; said expandable memberbeing in fluid communication with said lumen and positioned to expandagainst said at least one arm member.
 61. A device according to claim60, wherein said device includes three arm members and a distal end ofeach arm member sized and shaped to contact said aortic sinus wallsubstantially at a junction of said aortic sinus wall and leaflets ofsaid aorta.
 62. A device according to claim 60, wherein said expandablemember is a balloon.
 63. A device according to claim 60, wherein said atleast one arm member is shaped into a petal-like shape.
 64. A deviceaccording to claim 60, wherein at least one stress risers is disposed onsaid at least one arm member.
 65. A method of treating a valvecomprising: identifying a valve having diseased leaflets; delivering atleast one arm member to contact an aortic sinus wall at the junction ofsaid wall with at least one of said diseased leaflets and therebystabilize said at least one arm member; and, moving said leafletsoutwardly so as to contact said arm members.
 66. A method according toclaim 65, wherein said delivering at least one arm member includesdelivering at least one petal shaped arm member.
 67. A method accordingto claim 66, wherein said delivering at least one petal shaped armmember includes delivering three petal shaped arm members.
 68. A methodaccording to claim 65, wherein the moving of said leaflets outwardlyincludes delivering an expandable member to said leaflets and expandingsaid leaflets against said petal shaped arm members.
 69. A methodaccording to claim 65, wherein the moving of said leaflets outwardlyincludes moving said leaflets against stress risers disposed on saidleaflets.
 70. A device for treating a heart valve comprising: a catheterhaving a lumen; a mesh anchoring disk disposed towards a distal regionof said catheter; an expandable member disposed on said catheterproximal to said anchoring disk; and, said expandable member sized andshaped to open said valve when said expandable member is in an expandedstate.
 71. A device according to claim 70, wherein said mesh anchoringdisk is self expanding.
 72. A device according to claim 70, wherein saidmesh anchoring disk is movable between a compressed state and anexpanded state.
 73. A device according to claim 72, wherein said meshanchoring disk extends longitudinally along said catheter when in saidcompressed state.
 74. A device according to claim 70, wherein said meshanchoring disk is comprised of a plurality of semi-rigid, elongatedelements.
 75. A method of treating a heart valve comprising: identifyinga diseased valve; delivering an expandable member to said diseasedvalve; deploying a mesh anchoring disk such that a periphery of saiddisk engages walls in a region of said diseased valve and therebysecures said expandable member in place in said valve; and, expandingsaid expandable member to open said diseased valve.
 76. A methodaccording to claim 75, wherein the deploying of said mesh anchoring diskincludes allowing said mesh anchoring disk to self expand.
 77. A methodaccording to claim 75, wherein the deploying of said mesh anchoring diskincludes actively expanding said mesh anchoring disk.
 78. A methodaccording to claim 75, further comprising allowing blood to perfusethrough said mesh after deployment of said mesh anchoring disk.
 79. Amethod according to claim 75, further comprising delivering a prostheticvalve with said mesh anchoring disk.
 80. A method according to claim 79,further comprising delivering a prosthetic valve having drug elutingproperties.
 81. A device for delivering a drug to a heart valvecomprising: a sheath; a ring member movable within said sheath; an insitu treatment mechanism disposed on said ring member; said ring memberbeing detachable from said device; and, said ring member being sized andshaped for placement in a left ventricular outflow tract of an aorta.82. The device according to claim 81, wherein said in situ treatmentmechanism includes a decalcification agent.
 83. The device according toclaim 81, wherein said in situ treatment mechanism includes ananti-fibrotic agent.
 84. The device according to claim 81, wherein saidin situ treatment mechanism includes an anti-restenotic agent.
 85. Thedevice according to claim 81, wherein said in situ treatment mechanismincludes an agent to stabilize a stenosis of said heart valve.
 86. Thedevice according to claim 81, wherein said in situ treatment mechanismincludes an agent to reverse a stenosis of said heart valve.
 87. Thedevice according to claim 81, wherein said in situ treatment mechanismincludes a plurality of drug eluting fingers disposed around said ringmember, said fingers extending into contact with leaflets of a valve.88. The device according to claim 81, wherein said in situ treatmentmechanism includes a plurality of drug eluting pods disposed on saidring member.
 89. The device according to claim 88, wherein said drugeluting pods are T-shaped.
 90. The device according to claim 88, whereinsaid drug eluting pods are L-shaped.
 91. A device for treating a heartvalve comprising: a post; an in situ treatment agent disposed on saidpost; a retention barb disposed on said post; and, said post sized andshaped for placement in a leaflet of said heart valve.
 92. A device fortreating a heart valve comprising: a membrane; an in situ treatmentagent disposed on said membrane; said membrane sized and shaped tooverlay a leaflet of said heart valve; and, at least one post forsecuring said membrane in place on said leaflet.
 93. A method oftreating a diseased valve comprising: performing a valvuloplasty on saiddiseased valve; and placing an implant in the region of said diseasedvalve, said implant having an in situ treatment agent disposed thereon.